You are here: Home: Audio Program Guide: BCU 3 | 2006 Audio: BCU 3 | 2006
 
  Go to interview with Kevin R Fox, MD
Go to interview with William J Gradishar, MD
Go to interview with Professor John F R Robertson,
MB, ChB, BSc, MD
Go to interview with Patrick I Borgen, MD
 

Go to Miami Breast Cancer Conference Tumor Panel Discussion on Adjuvant Systemic Therapy

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Kevin R Fox, MD
Director, Rena Rowan Breast Center
Associate Professor of Medicine
University of Pennsylvania
Cancer Center
Philadelphia, Pennsylvania		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Ovarian suppression concurrent with adjuvant chemotherapy to preserve ovarian functioning
Track 3 SWOG trial of chemotherapy with or without ovarian suppression in patients with ER-negative disease
Track 4 Potential rationale for the failure of ovarian suppression during chemotherapy to preserve fertility
Track 5 Natural history of ovarian functioning
Track 6 Ovarian stimulation, ova recovery, fertilization and cryopreservation to preserve fertility

Track 7 Selection of adjuvant chemotherapy for women who want to preserve fertility
Track 8 Methotrexate/fluorouracil as a therapeutic option for avoiding amenorrhea
Track 9 Effect of pregnancy on risk of recurrence in patients with previously treated breast cancer
Track 10 Importance of barrier contraception while receiving systemic therapy
Track 11 Impact of tamoxifen and chemotherapy on fetal outcomes during pregnancy
Track 12 Safety to a fetus of sentinel lymph node biopsy
Track 13 Clinical trials of adjuvant hormonal therapy in premenopausal patients
Track 14 Utility of ovarian suppression in combination with chemotherapy and tamoxifen
Track 15 Implications of data from adjuvant aromatase inhibitor trials on clinical practice
Track 16 Aromatase inhibitors in women with chemotherapy induced amenorrhea
Track 17 Future clinical research questions in patients with ER/PR-positive tumors
Track 18 Adjuvant trastuzumab monotherapy
Track 19 Use of fulvestrant in clinical practice
     
William J Gradishar, MD
Director, Breast Medical Oncology
Associate Professor of Medicine
Robert H Lurie Comprehensive
Cancer Center
Northwestern University Feinberg
School of Medicine
Chicago, Illinois		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Clinical trial results with nanoparticle albumin-bound (nab) paclitaxel
Track 3 Clinical use of single-agent nab paclitaxel for metastatic disease
Track 4 Comparison of neurotoxicity between paclitaxel and nab paclitaxel
Track 5 Predictors of response to nab paclitaxel
Track 6 Optimal first-line taxane therapy

Track 7 US Oncology trial results comparing adjuvant AC versus TC (docetaxel/cyclophosphamide)
Track 8 ECOG-E1199: Evaluating type and schedule of taxanes
Track 9 ECOG-E2100: Paclitaxel with or without bevacizumab as first-line therapy for metastatic disease
Track 10 Continuation of bevacizumab upon disease progression
Track 11 Impact of cost and reimbursement on the use of novel therapeutics
Track 12 First-line therapy for patients with minimally symptomatic disease
Track 13 Selection of first-line therapy for chemotherapy-naïve patients
Track 14 First-line therapy for patients progressing after adjuvant taxane therapy
Track 15 Use of capecitabine in the first-line metastatic setting
Track 16 EFECT: Evaluation of Fulvestrant and Exemestane Clinical Trial
Track 17 SoFEA: Study of Fulvestrant with or without concomitant Exemestane versus Anastrozole
Track 18 Aromatase inhibitors plus an LHRH agonist for premenopausal patients with metastatic disease
Track 19 High-dose fulvestrant in premenopausal patients
     
Professor John F R Robertson, MB, ChB, BSc, MD
Professor of Surgery
Head of Academic Division of Breast Surgery
University of Nottingham
City Hospital
Nottingham, United Kingdom		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Distinction between sequencing and switching from tamoxifen to an aromatase inhibitor
Track 3 Response to hormonal therapy in patients with ER-negative disease
Track 4 Potential rationale for response to exemestane after a nonsteroidal aromatase inhibitor
Track 5 Clinical trials of fulvestrant and aromatase inhibitors in the metastatic setting
Track 6 Results of combining anastrozole and tamoxifen in the ATAC trial

Track 7 Ongoing trials evaluating fulvestrant in combination with aromatase inhibitors
Track 8 Combination endocrine therapy for premenopausal patients with ER-positive disease
Track 9 Clinical trial results of high-dose fulvestrant in premenopausal patients
Track 10 Delayed adjuvant fulvestrant after standard endocrine therapy
     
Patrick I Borgen, MD
Professor of Surgery
Weill Medical College of Cornell University
Chief, Breast Service
Department of Surgery
Memorial Sloan-Kettering Cancer Center
New York, New York		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Impact of margin status on re-excision and local control
Track 3 Partial breast irradiation techniques evaluated in clinical trials
Track 4 Postlumpectomy radiation therapy in women over age 70
Track 5 Postlumpectomy radiation therapy and hormonal therapy for women with DCIS
Track 6 Perspective on the role of aromatase inhibitors in the prevention and adjuvant settings

Track 7 Utility of the Oncotype DX™ assay in clinical practice
Track 8 Clinical indications for the use of sentinel lymph node biopsy
Track 9 Axillary dissection after identification of a positive sentinel node
Track 10 False-negative rates in sentinel lymph node biopsies

     
Miami Breast Cancer Conference Tumor Panel Discussion on Adjuvant Systemic Therapy
  
  Click here to download the entire conference  
     


Adjuvant trastuzumab for patients with HER2-positive disease

  
Track 1 Introduction
Track 2 Overview of adjuvant trastuzumab trial results
Track 3 Efficacy of adjuvant trastuzumab
Track 4 Adjuvant trastuzumab and cardiac safety
Track 5 Adjuvant dose-dense AC T with trastuzumab
Track 6 Coamplification of HER2 and topoisomerase II and benefit from anthracycline-based chemotherapy
Track 7 Utility of the Oncotype DX assay in patients with HER2-positive disease
Track 8 Use of adjuvant trastuzumab monotherapy
Track 9 Delayed adjuvant trastuzumab
Track 10 Incorporating adjuvant trastuzumab data into the Adjuvant! Online program
Track 11 Impact of tumor size and nodal status on the use of adjuvant trastuzumab
     

Adjuvant Endocrine Therapy for Patients with ER- and/or PR-Positive Disease

  
Track 1 Clinical trials evaluating aromatase inhibitors in the neoadjuvant setting
Track 2 Overview of aromatase inhibitor trials
Track 3 Aromatase inhibitors versus tamoxifen
Track 4 Bone effects with aromatase inhibitors
Track 5 Gynecologic side effects with aromatase inhibitors and tamoxifen
Track 6 Time course of recurrence of ER/PR-positive disease
Track 7 Extended adjuvant therapy with aromatase inhibitors
     

Selection and Schedule of Adjuvant Chemotherapy

  
Track 1 Historical development of adjuvant chemotherapy
Track 2 ECOG-E1199 adjuvant trial: Evaluating type and schedule of taxanes
Track 3 GEICAM 9906: Adjuvant FE90C versus FE90C followed by weekly paclitaxel
Track 4 US Oncology adjuvant trial comparing AC to TC
Track 5 Anthracycline-versus nonanthracycline-based adjuvant chemotherapy
Track 6 Prediction of response to adjuvant chemotherapy